Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on September 14, 2012, reporting events occurring on September 12, 2012. The filing addresses Item 5.02 regarding the departure of a senior officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and separation terms.
Material Changes
Effective September 12, 2012, John Feeney, M.D., terminated his employment as Chief Medical Officer. The Company is obligated to provide the following severance benefits subject to the execution of a Separation and Release Agreement:
- Cash payment of monthly base salary for 12 months.
- An amount equal to his annual target bonus at the rate in effect at termination.
- Payment of monthly COBRA premiums until the earliest of the end of the 12-month period, expiration of coverage, or acquisition of substantially equivalent new coverage.
- Acceleration of stock option vesting by adding three months to the actual period of service completed.
- Extension of the exercise period for vested options to six months following termination.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary, or specific risk factors beyond the immediate impact of the executive departure.
Investor Verification Checklist
- Confirm the execution of the Separation and Release Agreement by Dr. Feeney to validate the severance obligations.
- Verify the specific dollar amounts for the 12-month salary continuation and the annual target bonus.
- Assess the impact of the Chief Medical Officer departure on ongoing clinical trials or regulatory submissions.
- Review the Company's succession plan for the Chief Medical Officer role.